Cellectricon and Censo Biotechnologies collaborate to offer high-quality Human iPSC-based discovery services for CNS and pain research
Mölndal, Sweden and Cambridge, UK – 8th September 2016 – Cellectricon AB, a leading provider of advanced cell-based discovery screening services, today announced a commercial collaboration with UK-based stem cell technology company Censo Biotechnologies Ltd. Under the agreement, the parties will provide a suite of high-quality Human iPSC based discovery services to support both preclinical neuroscience and chronic pain research.
“Through our collaboration with Censo, we are able to significantly enhance our discovery services offering for CNS and pain research”, said Cellectricon’s CEO David Burns. “Censo’s extensive stem cell knowledge complements our current expertise and screening service offering in the field of neuroscience. This collaboration provides the opportunity to meet industry’s demands for drug discovery models that are closer, and therefore more relevant, to humans.
Censo’s CEO Aidan Courtney added: “Censo is committed to the use of ethically approved Human iPSCs and their derivatives to advance drug discovery. There is an excellent alignment between Censo and Cellectricon and we are very excited about this collaboration. With our extensive expertise, we can provide important stem cell knowledge that adds further value to Cellectricon’s proprietary discovery services”.
For more information on Cellectricon’s Pain and CNS Discovery Services, please visit the Discovery Services Page: www.cellectricon.com
For immediate release
Dr. Mattias Karlsson – Chief Technology Officer
t: +46 (0)733 67 35 00 e: Mattias.firstname.lastname@example.org
Kevin Bruce – Head of Commercial
T: +44 (0)131 440 6541 e: email@example.com
Alto Marketing Limited
Kelly Buggy – Account Manager
t: +44 (0)1489 557672 e: firstname.lastname@example.org